Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
NIVO3+IPI1 versus NIVO1+IPI3 bij gevorderd melanoom: CheckMate 511
apr 2019 | Dermato-oncologie, Immuuntherapie